| HOME >> BIOLOGY >> TECHNOLOGY |
Operating income (loss)
before other income and
expense, minority
interest, income taxes
and discontinued
operations $(2,278,474) $773,477 $(7,083,303) $1,676,915
Other income (expense),
net:
Other income (expense),
net 10,793 (410) 11,318 163,889
Interest income (expense),
net (240,311) (33,790) (313,277) (62,406)
Total other income
(expense), net $(229,518) $(34,200) $(301,959) $101,483
Income (loss) before
minority interest,
income taxes and
discontinued operations $(2,507,992) $739,277 $(7,385,262) $1,778,398
Minority interest benefit
(expense) 202,495 319,998 644,951 984,328
Income tax benefit
(expense) 729,951 (300,000) 2,415,353 (888,000)
Net income (loss) from
continuing operations $(1,575,546) $759,275 $(4,324,958) $1,874,726
Discontinued operations:
Revenues: PBM $-- $-- $2,925,139 $--
Cost of goods sold: PBM -- -- 2,904,274 --
Gross profit: PBM $-- $-- 20,865 $--
Selling, general and
administrative
expenses: PBM -- -- 20,785 --
PBM segment exit income
(expense) -- -- 8,300 --
Discontinued operations
net income (net of
income tax) $-- $-- $8,380 $--
Net income (loss) $(1,575,546) $759,275 $(4,316,578) $1,874,726
Preferred stock dividends 100,001 75,000 308,336 225,000
Net income (loss)
available to common
sha
'/>"/>
| SOURCE GeoPharma, Inc. Copyright©2008 PR Newswire. All rights reserved |